Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company focused on metabolic health, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Board of Directors granted a non-qualified stock option award to purchase 40,000 shares of common stock to a new non-executive employee under its 2024 Inducement Equity Incentive Plan.
The stock options have an exercise price of $5.28 per share, equal to the closing price of Skye's common stock on August 22, 2024. The shares will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 monthly installments, subject to continued employment. This grant is part of Skye's strategy to attract new talent and align employee interests with company growth.
Skye Bioscience (Nasdaq: SKYE), una società biofarmaceutica in fase clinica focalizzata sulla salute metabolica, ha annunciato un'indennità di incentivo ai sensi della Nasdaq Listing Rule 5635(c)(4). Il Consiglio di Amministrazione della società ha concesso un premio di opzione su azioni non qualificate per l'acquisto di 40.000 azioni di azioni ordinarie a un nuovo dipendente non esecutivo nell'ambito del suo Piano di Incentivazione Azionaria 2024.
Le opzioni su azioni hanno un prezzo di esercizio di $5.28 per azione, equivalente al prezzo di chiusura delle azioni ordinarie di Skye del 22 agosto 2024. Le azioni matureranno in quattro anni, con il 25% che matura nel primo anniversario e il restante che matura in 36 rate mensili, soggetto a un'occupazione continua. Questa concessione fa parte della strategia di Skye per attrarre nuovi talenti e allineare gli interessi dei dipendenti con la crescita dell'azienda.
Skye Bioscience (Nasdaq: SKYE), una compañía biofarmacéutica en etapa clínica enfocada en la salud metabólica, ha anunciado una concesión de incentivos bajo la Regla de Listado 5635(c)(4) de Nasdaq. La Junta Directiva de la compañía otorgó una opción sobre acciones no calificadas para comprar 40,000 acciones de acciones comunes a un nuevo empleado no ejecutivo bajo su Plan de Incentivo de Equidad de Inducción 2024.
Las opciones sobre acciones tienen un precio de ejercicio de $5.28 por acción, equivalente al precio de cierre de las acciones comunes de Skye el 22 de agosto de 2024. Las acciones se adquirirán durante cuatro años, con el 25% adquiriéndose en el primer aniversario y el resto en 36 cuotas mensuales, sujeto a la continuidad del empleo. Esta concesión es parte de la estrategia de Skye para atraer nuevos talentos y alinear los intereses de los empleados con el crecimiento de la empresa.
Skye Bioscience (Nasdaq: SKYE)는 대사 건강에 중점을 둔 임상 단계의 생명공학 회사로, Nasdaq 상장 규칙 5635(c)(4)에 따른 유인 보상을 발표했습니다. 회사의 이사회는 2024년 유인 주식 인센티브 계획에 따라 새로운 비임원 직원에게 40,000주의 보통주를 구매할 수 있는 비자격 주식 옵션을 부여했습니다.
주식 옵션의 행사가격은 $5.28 per share로, 2024년 8월 22일 Skye의 보통주 마감 가격과 동일합니다. 주식은 4년 동안 분할 상환되며, 첫 해 기념일에 25%가 벤처되고, 나머지는 36개월에 걸쳐 분할 상환될 예정이며, 지속적인 고용이 조건입니다. 이 보상은 신규 인재를 유치하고 직원의 이익을 회사 성장과 일치시키려는 Skye의 전략의 일환입니다.
Skye Bioscience (Nasdaq: SKYE), une entreprise biopharmaceutique en phase clinique axée sur la santé métabolique, a annoncé un accord d'incitation conformément à la règle de cotation 5635(c)(4) de Nasdaq. Le conseil d'administration de la société a accordé une prime optionnelle non qualifiée permettant d'acheter 40 000 actions d'actions ordinaires à un nouvel employé non exécutif dans le cadre de son Plan d'Incitation aux Actions de 2024.
Les options sur actions ont un prix d'exercice de $5.28 par action, correspondant au prix de clôture des actions ordinaires de Skye le 22 août 2024. Les actions seront acquises sur une période de quatre ans, avec 25 % acquises à l'anniversaire de la première année et le reste en 36 versements mensuels, sous réserve d'un emploi continu. Cette attribution fait partie de la stratégie de Skye pour attirer de nouveaux talents et aligner les intérêts des employés sur la croissance de l'entreprise.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf metabolische Gesundheit konzentriert, hat einen Anreizzuschuss gemäß der Nasdaq Listing Rule 5635(c)(4) angekündigt. Der Vorstand des Unternehmens hat einem neuen nicht-executive Mitarbeiter eine nicht qualifizierte Aktienoptionsauszeichnung für den Kauf von 40.000 Aktien des Stammkapitals im Rahmen seines Anreiz-Aktien-Plan 2024 gewährt.
Die Aktienoptionen haben einen Ausübungspreis von $5.28 pro Aktie, was dem Schlusskurs der Stammaktien von Skye am 22. August 2024 entspricht. Die Aktien werden über vier Jahre hinweg zur Verfügung stehen, wobei 25% am ersten Jahrestag und der Rest in 36 monatlichen Raten fällig wird, vorausgesetzt, dass die Anstellung fortgesetzt wird. Dieser Zuschuss ist Teil der Strategie von Skye, neue Talente zu gewinnen und die Interessen der Mitarbeiter mit dem Wachstum des Unternehmens in Einklang zu bringen.
- Skye is attracting new talent with stock option incentives
- The company is listed on Nasdaq, indicating market visibility
- None.
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on August 22, 2024, the Board of Directors granted a non-qualified stock option award to purchase 40,000 shares of its common stock to one new non-executive employee under the Company’s 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Skye, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Skye, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye started a Phase 2 clinical trial in obesity in August 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: https://www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development, business strategy, the timing of clinical trials and the therapeutic potential of our therapeutic candidates. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
What was the exercise price of the stock options granted by Skye Bioscience (SKYE)?
How many shares of common stock were included in the stock option award granted by Skye Bioscience (SKYE)?
What is the vesting schedule for the stock options granted by Skye Bioscience (SKYE)?
Under which plan did Skye Bioscience (SKYE) grant the inducement stock options?
